Hereditary cancer predisposition syndromes

Journal of Clinical Oncology

Volumn 23, Issue 2, 2005, Pages 276-292

  Garber, Judy E ^a   Offit, Kenneth ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CA 125 ANTIGEN; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; ESTROGEN PLUS PROGESTIN; FINASTERIDE; ORAL CONTRACEPTIVE AGENT; RALOXIFENE; SULINDAC; TAMOXIFEN; UNCLASSIFIED DRUG;

ADENOMATOUS POLYP; BASAL CELL NEVUS SYNDROME; BREAST CANCER; CANCER GENETICS; CANCER RISK; CANCER SUSCEPTIBILITY; CLINICAL TRIAL; COLORECTAL CANCER; COWDEN SYNDROME; FAMILIAL CANCER; GENE MUTATION; HUMAN; MELANOMA; MULTIPLE ENDOCRINE NEOPLASIA; OVARY CANCER; PANCREAS CANCER; PARAGANGLIOMA; PATHOGENESIS; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RETINOBLASTOMA; REVIEW; STOMACH CANCER; SURGICAL TECHNIQUE; TUMOR SUPPRESSOR GENE; BREAST TUMOR; GASTROINTESTINAL TUMOR; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; MUTATION; NEOPLASM;

BREAST NEOPLASMS; GASTROINTESTINAL NEOPLASMS; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HUMANS; MUTATION; NEOPLASMS; NEOPLASTIC SYNDROMES, HEREDITARY; RETINOBLASTOMA;

EID: 13744263782     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.10.042     Document Type: Review

References (198)

1. Statement of the American Society of Clinical Oncology: Genetic testing for cancer susceptibility, Adopted on February 20, 1996. J Clin Oncol 14:1730-1740, 1996
2. American Society of Clinical Oncology policy statement update: Genetic testing for cancer susceptibility. J Clin Oncol 21:2397-2406, 2003
3. Resource document for curriculum development in cancer genetics education. American Society of Clinical Oncology. J Clin Oncol 15:2157-2169, 1997
4. Offit K, Garber J, Grady M, et al: ASCO Curriculum: Cancer Genetics & Cancer Predisposition Testing, 2nd Edition. Alexandria, VA, American Society of Clinical Oncology, 2004
5. Friend SH, Bernards R, Rogelj S, et al: A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 323:643-646, 1986
6. Knudson AG, Jr.: Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A 68:820-823, 1971
7. Lohmann DR, Gallie BL: Retinoblastoma: Revisiting the model prototype of inherited cancer. Am J Med Genet 129C:23-28, 2004
8. Marcus DM, Brooks SE, Left G, et al: Trilateral retinoblastoma: insights into histogenesis and management. Surv Ophthalmol 43:59-70, 1998
9. Eng C, Li FP, Abramson DH, et al: Mortality from second tumors among long-term survivors of retinoblastoma. J Natl Cancer Inst 85:1121-1128, 1993
10. Gallie BL: Predictive testing for retinoblastoma comes of age. Am J Hum Genet 61:279-281, 1997
11. Harbour JW: Molecular basis of low-penetrance retinoblastoma. Arch Ophthalmol 119:1699-1704, 2001
12. Cohen JG, Dryja TP, Davis KB, et al: RB1 genetic testing as a clinical service: a follow-up study. Med Pediatr Oncol 37:372-378, 2001
13. Girardet A, Hamamah S, Anahory T, et al: First preimplantation genetic diagnosis of hereditary retinoblastoma using informative microsatellite markers. Mol Hum Reprod 9:111-116, 2003
14. Noorani HZ, Khan HN, Gallie BL, et al: Cost comparison of molecular versus conventional screening of relatives at risk for retinoblastoma. Am J Hum Genet 59:301-307, 1996
15. Lohmann DR, Gerick M, Brandt B, et al: Constitutional RB1-gene mutations in patients with isolated unilateral retinoblastoma. Am J Hum Genet 61:282-294, 1997
16. Li FP, Abramson DH, Tarone RE, et al: Hereditary retinoblastoma, lipoma, and second primary cancers. J Natl Cancer Inst 89:83-84, 1997
17. Fletcher O, Easton D, Anderson K, et al: Lifetime risks of common cancers among retinoblastoma survivors. J Natl Cancer Inst 96:357-363, 2004
18. Antoniou A, Pharoah PD, Narod S, et al: Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: A combined analysis of 22 studies. Am J Hum Genet 72:1117-1130, 2003
19. Pharoah PD, Antoniou A, Bobrow M, et al: Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet 31:33-36, 2002
20. Whittemore AS, Gong G, Itnyre J: Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: Results from three U.S. population-based case-control studies of ovarian cancer. Am J Hum Genet 60:496-504, 1997
21. Ford D, Easton DF, Stratton M, et al: Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 62:676-689, 1998
22. Frank TS, Deffenbaugh AM, Reid JE, et al: Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: Analysis of 10,000 individuals. J Clin Oncol 20:1480-1490, 2002
23. Varley JM, Evans DG, Birch JM: Li-Fraumeni syndrome-a molecular and clinical review. Br J Cancer 76:1-14, 1997
24. Balmain A, Gray J, Ponder B: The genetics and genomics of cancer. Nat Genet 33:238-244, 2003 (suppl)
25. Chappuis PO, Nethercot V, Foulkes WD: Clinico-pathological characteristics of BRCA1-and BRCA2-related breast cancer. Semin Surg Oncol 18:287-295, 2000
26. Phillips KA, Andrulis IL, Goodwin PJ: Breast carcinomas arising in carriers of mutations in BRCA1 or BRCA2: Are they prognostically different? J Clin Oncol 17:3653-3663, 1999
27. Narod SA, Foulkes WD: BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer 4:665-676, 2004
28. Sorlie T, Tibshirani R, Parker J, et al: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100:8418-8423, 2003
29. Eisinger F, Nogues C, Birnbaum D, et al: BRCA1 and medullary breast cancer. JAMA 280:1227-1228, 1998
30. Rebbeck TR, Lynch HT, Neuhausen SL, et al: Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346:1616-1622, 2002
31. Kauff ND, Satagopan JM, Robson ME, et al: Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346:1609-1615, 2002
32. Boyd J, Sonoda Y, Federici MG, et al: Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 283:2260-2265, 2000
33. Lakhani SR, Manek S, Penault-Llorca F, et al: Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Clin Cancer Res 10:2473-2481, 2004
34. Levine DA, Argenta PA, Yee CJ, et al: Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations. J Clin Oncol 21:4222-4227, 2003
35. Cass I, Baldwin RL, Varkey T, et al: Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 97:2187-2195, 2003
36. Miki Y, Swensen J, Shattuck-Eidens D, et al: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66-71, 1994
37. Wooster R, Bignell G, Lancaster J, et al: Identification of the breast cancer susceptibility gene BRCA2. Nature 378:789-792, 1995
38. Kauff ND, Perez-Segura P, Robson ME, et al: Incidence of non-founder BRCA1 and BRCA2 mutations in high risk Ashkenazi breast and ovarian cancer families. J Med Genet 39:611-614, 2002
39. Thorlacius S, Sigurdsson S, Bjarnadottir H, et al: Study of a single BRCA2 mutation with high carrier frequency in a small population. Am J Hum Genet 60:1079-1084, 1997
40. Unger MA, Nathanson KL, Calzone K, et al: Screening for genomic rearrangements in families with breast and ovarian cancer identifies BRCA1 mutations previously missed by conformation-sensitive gel electrophoresis or sequencing. Am J Hum Genet 67:841-850, 2000
41. Begg CB: On the use of familial aggregation in population-based case probands for calculating penetrance. J Natl Cancer Inst 94:1221-1226, 2002
42. Risch HA, McLaughlin JR, Cole DE, et al: Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 68:700-710, 2001
43. Thompson D, Easton D: Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet 68:410-419, 2001
44. King MC, Marks JH, Mandell JB: Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302:643-646, 2003
45. Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium. J Natl Cancer Inst 91:1310-1316, 1999
46. Garcia-Higuera I, Taniguchi T, Ganesan S, et al: Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol Cell 7:249-262, 2001
47. Howlett NG, Taniguchi T, Olson S, et al: Biallelic inactivation of BRCA2 in Fanconi anemia. Science 297:606-609, 2002
48. Offit K, Levran O, Mullaney B, et al: Shared genetic susceptibility to breast cancer, brain tumors, and Fanconi anemia. J Natl Cancer Inst 95:1548-1551, 2003
49. Sharan SK, Morimatsu M, Albrecht U, et al: Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking BRCA2. Nature 386:804-810, 1997
50. Wagner JE, Tolar J, Levran O, et al: Germline mutations in BRCA2: Shared genetic susceptibility to breast cancer, early onset leukemia, and Fanconi anemia. Blood 103:3226-3229, 2004
51. Burke W, DaIy M, Garber J, et al: Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. JAMA 277:997-1003, 1997
52. Kuhl CK, Schrading S, Leutner CC, et al: Surveillance of high risk women with proven or suspected familial (hereditary) breast cancer: First mid-term results of a multi-modality clinical screening trial. Proc Amer Soc Clin Oncol 22:2 2003 (abstr 4)
53. Kriege M, Brekelmans CT, Boetes C, et al: Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 351:427-437, 2004
54. Warner E, Plewes DB, Hill KA, et al: Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 292:1317-1325, 2004
55. Robson ME, Offit K: Breast MRI for women with hereditary cancer risk. JAMA 292:1368-1370, 2004
56. Ziegler LD, Kroll SS: Primary breast cancer after prophylactic mastectomy. Am J Clin Oncol 14:451-454, 1991
57. Hartmann LC, Sellers TA, Schaid DJ, et al: Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 93:1633-1637, 2001
58. Meijers-Heijboer H, van Geel B, van Putten WL, et al: Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 345:159-164, 2001
59. Veronesi U, Maisonneuve P, Costa A, et al: Prevention of breast cancer with tamoxifen: Preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet 352:93-97, 1998
60. Eeles RA, Powles TJ: Chemoprevention options for BRCA1 and BRCA2 mutation carriers. J Clin Oncol 18:93S-99S, 2000
61. Narod SA, Brunet JS, Ghadirian P, et al: Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: A case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet 356:1876-1881, 2000
62. American CoP: Screening for ovarian cancer: Recommendations and rationale. Ann Intern Med 121:141-142, 1994
63. Lynch HT, Albano WA, Lynch JF, et al: Surveillance and management of patients at high genetic risk for ovarian carcinoma. Obstet Gynecol 59:589-596, 1982
64. Struewing JP, Watson P, Easton DF, et al: Prophylactic oophorectomy in inherited breast/ ovarian cancer families. J Natl Cancer Inst Monogr 17:33-35, 1995
65. Modan B, Hartge P, Hirsh-Yechezkel G, et al: Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med 345:235-240, 2001
66. Narod SA, Risch H, Moslehi R, et al: Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med 339:424-428, 1998
67. Narod SA, Dube MP, Klijn J, et al: Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 94:1773-1779, 2002
68. Li FP, Fraumeni JF, Jr.: Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med 71:747-752, 1969
69. Li FP, Fraumeni JF, Jr., Mulvihili JJ, et al: A cancer family syndrome in twenty-four kindreds. Cancer Res 48:5358-5362, 1988
70. Nichols KE, Malkin D, Garber JE, et al: Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. Cancer Epidemiol Biomarkers Prev 10:83-87, 2001
71. Strong LC: General keynote: Hereditary cancer: Lessons from Li-Fraumeni syndrome. Gynecol Oncol 88:34-7, 2003
72. Varley JM: Germline TP53 mutations and Li-Fraumeni syndrome. Hum Mutat 21:313-320, 2003
73. Birch JM, Blair V, Kelsey AM, et al: Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome. Oncogene 17:1061-1068, 1998
74. Lalloo F, Varley J, Ellis D, et al: Prediction of pathogenic mutations in patients with early-onset breast cancer by family history. Lancet 361:1101-1102, 2003
75. Toguchida J, Yamaguchi T, Dayton SH, et al: Prevalence and spectrum of germline mutations of the p53 gene among patients with sarcoma. N Engl J Med 326:1301-1308, 1992
76. Bell DW, Varley JM, Szydlo TE, et al: Heterozygous germ line hCHK2 mutations in LiFraumeni syndrome. Science 286:2528-2531, 1999
77. Varley J: TP53, hChk2, and the Li-Fraumeni syndrome. Methods Mol Biol 222:117-129, 2003
78. Eng C: Will the real Cowden syndrome please stand up: Revised diagnostic criteria. J Med Genet 37:828-830, 2000
79. Fackenthal JD, Marsh DJ, Richardson AL, et al: Male breast cancer in Cowden syndrome patients with germline PTEN mutations. J Med Genet 38:159-164, 2001
80. Li J, Yen C, Liaw D, et al: PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275:1943-1947, 1997
81. Eng C: Role of PTEN, a lipid phosphatase upstream effector of protein kinase B, in epithelial thyroid carcinogenesis. Ann N Y Acad Sci 968:213-221, 2002
82. Marsh DJ, Kum JB, Lunetta KL, et al: PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome. Hum Mol Genet 8:1461-1472, 1999
83. National Comprehensive Cancer Network: Guidelines for the detection, prevention and risk of cancer, genetics/familial high risk assessment-Cowden syndrome, http://www.nccn .org/physician_gls/f_guidelines.html
84. Hover AR, Cawthern T, McDanial W: Cowden disease. A hereditary polyposis syndrome diagnosable by mucocutaneous inspection. J Clin Gastroenterol 8:576-579, 1986
85. Campbell WJ, Spence RA, Parks TG: Familial adenomatous polyposis. Br J Surg 81:1722-1733, 1994
86. Burt RW, Leppert MF, Slattery ML, et al: Genetic testing and phenotype in a large kindred with attenuated familial adenomatous polyposis. Gastroenterology 127:444-451, 2004
87. Kinzler KW, Nilbert MC, Su LK, et al: Identification of FAP locus genes from chromosome 5q21. Science 253:661-665, 1991
88. Bertario L, Russo A, Sala P, et al: Multiple approach to the exploration of genotype-phenotype correlations in familial adenomatous polyposis. J Clin Oncol 21:1698-1707, 2003
89. Spirio L, Olschwang S, Groden J, et al: Alleles of the APC gene: An attenuated form of familial polyposis. Cell 75:951-957, 1993
90. Sieber OM, Lipton L, Crabtree M, et al: Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line mutations in MYH. N Engl J Med 348:791-799, 2003
91. Laken SJ, Petersen GM, Gruber SB, et al: Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC. Nat Genet 17:79-83, 1997
92. Syngal S, Schrag D, Falchuk M, et al: Phenotypic characteristics associated with the APC gene I1307K mutation in Ashkenazi Jewish patients with colorectal polyps. JAMA 284:857-860, 2000
93. King JE, Dozois RR, Lindor NM, et al: Care of patients and their families with familial adenomatous polyposis. Mayo Clin Proc 75:57-67, 2000
94. Hernegger GS, Moore HG, Guillem JG: Attenuated familial adenomatous polyposis: An evolving and poorly understood entity. Dis Colon Rectum 45:127-136, 2002
95. Hampel H, Peltomaki P: Hereditary colorectal cancer: risk assessment and management. Clin Genet 58:89-97, 2000
96. Giardiello FM, Yang VW, Hylind LM, et al: Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med 346:1054-1059, 2002
97. Parc YR, Olschwang S, Desaint B, et al: Familial adenomatous polyposis: Prevalence of adenomas in the ileal pouch after restorative proctocolectomy. Ann Surg 233:360-364, 2001
98. Phillips RK, Wallace MH, Lynch PM, et al: A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut 50:857-860, 2002
99. Lynch HT, de la Chapelle A: Hereditary colorectal cancer. N Engl J Med 348:919-932, 2003
100. Watson P, Lynch HT: Extracolonic cancer in hereditary nonpolyposis colorectal cancer. Cancer 71:677-685, 1993
101. Bailey-Wilson JE, Elston RC, Schuelke GS, et al: Segregation analysis of hereditary nonpolyposis colorectal cancer. Genet Epidemiol 3:27-38, 1986
102. Vasen HF, Taal BG, Griffioen G, et al: Clinical heterogeneity of familial colorectal cancer and its influence on screening protocols. Gut 35:1262-1266, 1994
103. Aarnio M, Sankila R, Pukkala E, et al: Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 81:214-218, 1999
104. Vasen HF, Watson P, Mecklin JP, et al: New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 116:1453-1456, 1999
105. Rodriguez-Bigas MA, Boland CR, Hamilton SR, et al: A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: Meeting highlights and Bethesda guidelines. J Natl Cancer Inst 89:1758-1762, 1997
106. Umar A, Boland CR, Terdiman JP, et al: Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 96:261-268, 2004
107. Leach FS, Nicolaides NC, Papadopoulos N, et al: Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell 75:1215-1225, 1993
108. Fishel R, Lescoe MK, Rao MR, et al: The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 75:1027-1038, 1993
109. Bronner CE, Baker SM, Morrison PT, et al: Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature 368:258-261, 1994
110. Liu B, Parsons R, Papadopoulos N, et al: Analysis of mismatch repair genes in hereditary non-polyposis colorectal cancer patients. Nat Med 2:169-174, 1996
111. Wijnen JT, Vasen HF, Khan PM, et al: Clinical findings with implications for genetic testing in families with clustering of colorectal cancer. N Engl J Med 339:511-518, 1998
112. Liu T, Yan H, Kuismanen S, et al: The role of hPMS1 and hPMS2 in predisposing to colorectal cancer. Cancer Res 61:7798-7802, 2001
113. Offit K: MSH6 mutations in hereditary nonpolyposis colon cancer: Another slice of the pie. J Clin Oncol 22:4449-4451, 2004
114. Boland CR, Thibodeau SN, Hamilton SR, et al: A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: Development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 58:5248-5257, 1998
115. Aaltonen LA, Peltomaki P, Leach FS, et al: Clues to the pathogenesis of familial colorectal cancer. Science 260:812-816, 1993
116. Thibodeau SN, Bren G, Schaid D: Microsatellite instability in cancer of the proximal colon. Science 260:816-819, 1993
117. Lindor NM, Burgart LJ, Leontovich O, et al: Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol 20:1043-1048, 2002
118. Cunningham JM, Christensen ER, Tester DJ, et al: Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Res 58:3455-3460, 1998
119. Cunningham JM, Kim CY, Christensen ER, et al: The frequency of hereditary defective mismatch repair in a prospective series of unselected colorectal carcinomas. Am J Hum Genet 69:780-790, 2001
120. Jarvinen HJ, Mecklin JP, Sistonen P: Screening reduces colorectal cancer rate in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 108:1405-1411, 1995
121. Jarvinen HJ, Aarnio M, Mustonen H, et al: Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 118:829-834, 2000
122. Vasen HF, Nagengast FM, Khan PM: Interval cancers in hereditary non-polyposis colorectal cancer (Lynch syndrome). Lancet 345:1183-1184, 1995
123. Lynch HT, Smyrk T, Lynch J: An update of HNPCC (Lynch syndrome). Cancer Genet Cytogenet 93:84-99, 1997
124. Rodriguez-Bigas MA: Prophylactic colectomy for gene carriers in hereditary nonpolyposis colorectal cancer. Has the time come? Cancer 78:199-201, 1996
125. Lynch PM: COX-2 inhibition in clinical cancer prevention. Oncology (Huntingt) 15:21-26, 2001
126. Giardiello FM, Brensinger JD, Petersen GM: AGA technical review on hereditary colorectal cancer and genetic testing. Gastroenterology 121:198-213, 2001
127. Benson AB, 3rd, Choti MA, Cohen AM, et al: NCCN Practice Guidelines for Colorectal Cancer. Oncology (Huntingt) 14:203-212, 2000
128. Burke W, Petersen G, Lynch P, et al: Recommendations for follow-up care of individuals with an inherited predisposition to cancer. I. Hereditary nonpolyposis colon cancer. Cancer Genetics Studies Consortium. JAMA 277:915-919, 1997
129. Charlton A, Blair V, Shaw D, et al: Hereditary diffuse gastric cancer: predominance of multiple foci of signet ring cell carcinoma in distal stomach and transitional zone. Gut 53:814-820, 2004
130. Guilford PJ, Hopkins JB, Grady WM, et al: E-cadherin germline mutations define an inherited cancer syndrome dominated by diffuse gastric cancer. Hum Mutat 14:249-255, 1999
131. Graziano F, Humar B, Guilford P: The role of the E-cadherin gene (CDH1) in diffuse gastric cancer susceptibility: from the laboratory to clinical practice. Ann Oncol 14:1705-1713, 2003
132. Brooks-Wilson AR, Kaurah P, Suriano G, et al: Germline E-cadherin mutations in hereditary diffuse gastric cancer: Assessment of 42 new families and review of genetic screening criteria. J Med Genet 41:508-517, 2004
133. Chun YS, Lindor NM, Smyrk TC, et al: Germline E-cadherin gene mutations: Is prophylactic total gastrectomy indicated? Cancer 92:181-187, 2001
134. Huntsman DG, Carneiro F, Lewis FR, et al: Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations. N Engl J Med 344:1904-1909, 2001
135. Grady WM, Peek RM Jr: Hereditary diffuse gastric cancer: More answers or more questions? Gastroenterology 122:830-832, 2002
136. Weitzel JN, McCahill LE: The power of genetics to target surgical prevention. N Engl J Med 344:1942-1944, 2001
137. Klein AP, Brune KA, Petersen GM, et al: Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res 64:2634-2638, 2004
138. Klein AP, Beaty TH, Bailey-Wilson JE, et al: Evidence for a major gene influencing risk of pancreatic cancer. Genet Epidemiol 23:133-149, 2002
139. Vasen HF, Gruis NA, Frants RR, et al: Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden). Int J Cancer 87:809-811, 2000
140. Murphy KM, Brune KA, Griffin C, et al: Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. Cancer Res 62:3789-3793, 2002
141. Hahn SA, Greenhalf B, Ellis I, et al: BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst 95:214-221, 2003
142. Lal G, Liu G, Schmocker B, et al: Inherited predisposition to pancreatic adenocarcinoma: Role of family history and germ-line p16, BRCA1, and BRCA2 mutations. Cancer Res 60:409-416, 2000
143. Eberle MA, Pfutzer R, Pogue-Geile KL, et al: A new susceptibility locus for autosomal dominant pancreatic cancer maps to chromosome 4q32-34. Am J Hum Genet 70:1044-1048, 2002
144. Petersen GM, Hruban RH: Familial pancreatic cancer: Where are we in 2003? J Natl Cancer Inst 95:180-181, 2003
145. van der Heijden MS, Yeo CJ, Hruban RH, et al: Fanconi anemia gene mutations in young-onset pancreatic cancer. Cancer Res 63:2585-2588, 2003
146. Kutler DI, Singh B, Sstagopan J, et al: A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood 101:1249-1256, 2003
147. Hruban RH, Petersen GM, Goggins M, et al: Familial pancreatic cancer. Ann Oncol 10:69-73, 1999 (suppl 4)
148. Reimer RR, Clark WH, Jr., Greene MH, et al: Precursor lesions in familial melanoma. A new genetic preneoplastic syndrome. JAMA 239:744-746, 1978
149. Greene MH, Clark WH, Jr., Tucker MA, et al: Acquired precursors of cutaneous malignant melanoma. The familial dysplastic nevus syndrome. N Engl J Med 312:91-97, 1985
150. Bale SJ, Dracopoli NC, Tucker MA, et al: Mapping the gene for hereditary cutaneous malignant melanoma-dysplastic nevus to chromosome 1p. N Engl J Med 320:1367-1372, 1989
151. Goldstein AM, Dracopoli NC, Ho EC, et al: Further evidence for a locus for cutaneous malignant melanoma-dysplastic nevus (CMM/ DN) on chromosome 1p, and evidence for genetic heterogeneity. Am J Hum Genet 52:537-550, 1993
152. Cannon-Albright LA, Goldgar DE, Meyer LJ, et al: Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22. Science 258:1148-1152, 1992
153. Cannon-Albright LA, Meyer LJ, Goldgar DE, et al: Penetrance and expressivity of the chromosome 9p melanoma susceptibility locus (MLM). Cancer Res 54:6041-6044, 1994
154. Kamb A, Shattuck-Eidens D, Eeles R, et al: Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet 8:23-26, 1994
155. Zuo L, Weger J, Yang Q, et al: Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet 12:97-99, 1996
156. Goldstein AM, Fraser MC, Struewing JP, et al: Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N Engl J Med 333:970-974, 1995
157. Borg A, Sandberg T, Nisson K, et al: High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-postive melanoma families. J Natl Cancer Inst 92:260-1266, 2000
158. Bishop DT, Demenais F, Goldstein AM, et al: Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancel Inst 94:894-903, 2002
159. Hansen CB, Wadge LM, Lowstuter K, et al: Clinical germline genetic testing for melanoma. Lancet Oncol 5:314-319, 2004
160. Gorlin RJ, Goltz RW: Multiple nevoid basai-cell epithelioma, jaw cysts and bifid rib. A syndrome. N Engl J Med 262:908-912, 1960
161. Gorlin RJ: Nevoid basal-cell carcinoma syndrome. Medicine (Baltimore) 66:98-113, 1987
162. Strong LC: Genetic and environmental interactions. Cancer 40:1861-1866, 1977
163. Evans DG, Ladusans EJ, Rimmer S, et al: Complications of the naevoid basal cell carcinoma syndrome: Results of a population based study. J Med Genet 30:460-464, 1993
164. Cowan R, Hoban P, Kelsey A, et al: The gene for the naevoid basal cell carcinoma syndrome acts as a tumour-suppressor gene in medulloblastoma. Br J Cancer 76:141-145, 1997
165. Johnson RL, Rothman AL, Xie J, et al: Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science 272:1668-1671, 1996
166. Wicking C, Shanley S, Smyth I, et al: Most germ-line mutations in the nevoid basal cell carcinoma syndrome lead to a premature termination of the PATCHED protein, and no genotype-phenotype correlations are evident. Am J Hum Genet 60:21-26, 1997
167. Savino M, d'Apolito M, Fonnica V, et al: Spectrum of PTCH mutations in Italian nevoid basal cell carcinoma patients Hum Mut 24:441-442, 2004
168. Anand VK, Arrowood JP Jr, Krolls SO: Malignant potential of the odontogenic keratocyst. Otolaryngol Head Neck Surg 111:124-129, 1994
169. Smith JR, Freije D, Carpten JD, et al: Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science 274:1371-1374, 1996
170. Verhage BA, Kiemeney LA: Genetic susceptibility to prostate cancer: A review. Fam Cancer 2:57-67, 2003
171. Ingles SA, Ross RK, Yu MC, et al: Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst 89:166-170, 1997
172. Taylor JA, Hirvonen A, Watson M, et al: Association of prostate cancer with vitamin D receptor gene polymorphism Cancer Res 56:4108-4110, 1996
173. Kirchhoff T, Kauff ND, Mitra N, et al: BRCA mutations and risk of prostate cancer in Ashkenazi Jews. Clin Cancer Res 10:2918-2921, 2004
174. Littrup PJ, Goodman AC, Mettlin CJ. The benefit and cost of prostate cancer early detection. The Investigators of the American Cancer Society-National Prostate Cancer Detection Project. CA Cancer J Clin 43:134-149, 1993
175. Bratt O: Hereditary prostate cancer: clinical aspects. J Urol 168:906-913, 2002
176. McWhorter WP, Hernandez AD, Meikle AW, et al: A screening study of prostate cancer in high risk families. J Urol 148:826-828, 1992
177. Thompson IM, Goodman PJ, Tangen CM, et al: The influence of finasteride on the development of prostate cancer. N Engl J Med 349:215-224, 2003
178. Pang JT, Thakker RV: Multiple endocrine neoplasia type 1 (MENV). Eur J Cancer 30A: 1961-1968, 1994
179. Chandrasekharappa SC, Guru SC, Manickam P, et al: Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 276:404-407, 1997
180. Vasen HF, Lamers CB, Lips CJ: Screening for the multiple endocrine neoplasia syndrome type I. A study of 11 kindreds in The Netherlands. Arch Intern Med 149:2717-2722, 1989
181. Brandi ML, Gagel RF, Angeli A, et al: Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 86:5658-5671, 2001
182. Pacak K, Linehan WM, Eisenhofer G, et al: Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. Ann Intern Med 134:315-329, 2001
183. Lonser RR, Glenn GM, Walther M, et al: von Hippel Lindau disease. Lancet 361:2059-2067, 2003
184. Woodward ER, Eng C, McMahon R, et al: Genetic predisposition to phaeochromocytoma. Analysis of candidate genes GDNF, RET and VHL. Hum Mol Genet 6:1051-1056, 1997
185. Neumann HP, Bausch B, McWhinney SR, et al: Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 346:1459-1466, 2002
186. Maher ER, Erg C: The pressure uses update on the genetics of phaeochromocytoma Hum Mol Genet 11:2347-2354, 2002
187. Walter MM, Reiter R, Keiser HR, et al: Clinical and genetic characterisation, of pheochromocytoma in von Hippel-Lindau families: Comparison with sporadic pheochromocytoma gives insight into natural history of pheochromocytoma. J Urol 162:659-664, 1999
188. Bryant J, Farmer J, Kessler LJ, et al: Pheochromocytoma: the expanding genetic differential diagnosis. J Natl Cancer Inst 95:1196-1204, 2003
189. Eng C, Clayton O, Schuffenecker I, et al The relationship between specific RET protooncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA 276:1575-1579, 1996
190. Yip L, Lee JE, Shapiro SE, et al: Surgical management of hereditary pheochromocytoma. J Am Coll Surg 198:525-535, 2004
191. Baysal BE, Ferrell RE, Willett-Brozick JE, et al: Mutations in SDHD, a mitochondrial complex I: gene, in hereditary paraganglioma Science 287:848-851, 2000
192. Hensen EF, Jordanova ES, van Minderhout IJ, et al: Somatic loss of maternal chromosome 11 causes parent-of-origin-dependent inheritance in SDHD-linked paraganglioma and phaeochromocytoma families. Oncogene 23:4076-4083, 2004
193. Neumann HP, Pawlu C, Peczkowska M, et al: Distinct clinical features of paragangliomayndromes associated with SDHB and SDHD gene mutations, JAMA 292:943-951, 2004
194. Skinner MA, DeBenedetti MK, Moley JF, et al: Medullary thyroid carcinoma in children with multiple endocrine neoplasia types 2A and 2B. J Pediatr Surg 31:177-182, 1996
195. Lonser RR, Glenn GM, Walther M, et al: von Hippel-Lindau disease. Lancet 361:2059-2067, 2003
196. Maher ER, Kaelin WG, Jr.: von Hippel-Lindau disease. Medicine (Baltimore) 76:381-391, 1997
197. Eisenhofer G, Lenders JW, Linehan WM, et al: Plasma normetanephrine and metanephnne for detecting pheochromocytoma in von Hippel-Lindau disease and multiple endocrine neoplasia type 2. N Engl J Med 340:1872-1879, 1999
198. Rechitsky S, Verlinsky O, Chistokhina A, et al: Preimplantation genetic diagnosis for cancer predisposition. Reprod Biomed Online 5:148-155, 2002